Abundnz is a privately owned company which was founded in October 2011 by Dr. Robert-Jan Lamers. Abundnz offers advanced immunological and analytical support for biopharmaceutical companies and life sciences researchers. With the use of innovative analytical techniques, immunology research and in vitro testing we characterize the behaviour of innovative medicines like peptide and protein drugs, oligonucleotides and targeted drug delivery systems and we discover and validate biomarkers.
Abundnz has a unique platform to study the relation between side effects of drugs and immune response. We have developed a technology called pAMS to determine the clearance profile of innovative medicines in an early phase of drug development.